Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis - Yahoo Finance
6/27/2022 12:00:00 AM2 years 10 months ago
by Business Wire
by Business Wire
SOUTH SAN FRANCISCO, Calif., June 27, 2022--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing...
- 11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months
- 6 of 17 patients (35.2%) achieved a … [+10273 chars] full article...